Suicide gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system combined with monocyte chemoattractant protein-1 (MCP-1) provides significant antitumor efficacy. The current study was designed to evaluate the antitumor immunity of a newly developed membrane-bound form of MCP-1 (mMCP-1) in an immunocompetent mouse model of hepatocellular carcinoma (HCC). A recombinant adenovirus vector (rAd) harboring the human MCP-1 gene and the membrane-spanning domain of the CX3CL1 gene was used. Large amounts of MCP-1 protein were expressed and accumulated on the tumor cell surface. The growth of subcutaneous tumors was markedly suppressed when tumors were treated with mMCP-1, as compared with soluble MCP-1, in combination with the HSV-tk/GCV system (Po0.01). The numbers of Mac-1-, CD4-and CD8a-positive cells were significantly higher in tumor tissues (Po0.05), and tumor necrosis factor (TNF) mRNA expression levels with mMCP-1 were almost five-fold higher than those with soluble MCP-1. These results indicate that the delivery of the mMCP-1 gene greatly enhanced antitumor effects following the apoptotic stimuli by promoting the recruitment and activation of macrophages and T lymphocytes, suggesting a novel strategy of immune-based gene therapy in the treatment of patients with HCC.
INTRODUCTION
In spite of the recent development of locoregional treatments for hepatocellular carcinoma (HCC), the frequency of tumor recurrence remains high, probably because of insufficient therapeutic effects and the multicentric development of HCC in cirrhotic liver. 1 --3 Non-surgical treatments of HCC, such as radiofrequency ablation, transcatheter arterial embolization and transcatheter arterial chemotherapy induce apoptosis of HCC cells, but these treatments do not enhance antitumoral immunity sufficiently. Thus, gene therapy aimed at enhancing antitumor immune responses may be a promising approach to prevent HCC recurrence, when it is combined with non-surgical maneuvers.
We previously reported that monocyte chemoattractant protein-1 (MCP-1) gene delivery using recombinant adenovirus vector (rAd) in vivo can enhance the efficacy of suicide gene therapy consisting of the delivery of rAd containing herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir (GCV) in models of HCC 4, 5 and colon cancer. 6 We further demonstrated that the antitumor effects depended on the activation of macrophages. 4, 5 The adenovirus-specific spatial and temporal expression pattern may result in the production of the transgene for a limited time. 7 Mirroring these characteristics, the adenovirus vector-mediated delivery of the MCP-1 gene alone was not sufficient to reduce tumor growth. 5 To circumvent this bottleneck, sustained expression of MCP-1 at the tumor site may be required to enhance the efficacy of the gene therapy using the MCP-1 gene. Systemic or local administration of cytokines has been used to enhance the antitumor immune response induced by many cancer vaccines. However, the systemic administration of cytokines resulted in unwanted side effects. Recently, tumor therapy that uses a membrane-bound form of cytokine was developed to reduce the side effects of cytokine in the systemic circulation. These experiments revealed that the membrane-bound form of cytokine not only reduced the side --effects, but enhanced the antitumor effects by prolonging the half-life of cytokines in the tumor microenvironment. 8 These observations prompted us to design the adenovirus vector driving the expression of membrane-bound form of MCP-1 (mMCP-1) and to evaluate its antitumor effects in a model of HCC. We demonstrated that the delivery of the mMCP-1 gene markedly augmented HSV-tk/GCV suicide gene therapy, compared with that of the soluble MCP-1 (sMCP-1).
MATERIALS AND METHODS

Recombinant adenovirus vectors
Ad-mMCP-1 ( Figure 1a) harboring the human MCP-1 gene and the membranespanning domain of the CX3CL1 gene driven by the human cytomegalovirus immediate early promoter/enhancer was prepared, purified and titrated according to the protocols supplied by the manufacturer (Takara, Tokyo, Japan). The human MCP-1/CX3CL1 (fractalkine) chimera was designed as follows: DNA encoding a fragment of human CX3CL1 spanning the intracellular, transmembrane and partial extracellular region was amplified from the full-length CX3CL1 cDNA by PCR with the following primers (5 0 -GCGAGCTCGGGTACCTTCGAGAAGCAGATCG-3 0 and 5 0 -GCGAATTCAGATT GTCACACGGGCACAGG-3 0 ). SacI, KpnI and EcoRI restriction enzyme sites were added at the 5 0 and 3 0 ends of this fragment. MCP-1 was also amplified by PCR with the following primers (5 0 -GCGAGCTCGCCAGCAT-GAAAGTCTCTGCCG-3 0 and 5 0 -GCGGTACCAGTCTTCGGAGTTTGGGTTTGC-3 0 ). SacI and KpnI restriction enzyme sites were added at the 5 0 and 3 0 ends of this fragment. The CX3CL1 and MCP-1 DNA fragments were digested with restriction enzymes by coligation into the SacI and EcoRI sites of pSTBlue-1 (Novagen, Darmstadt, Germany), generating pSTBlue-1-mMCP-1. Then, pSTBlue-1-mMCP-1 was digested by NotI and BamHI restriction enzymes and the fragment was inserted into the pShuttle Vector (Clontech Laboratories, Mountain View, CA) under the control of cytomegalovirus immediate early promoter/enhancer, generating pShuttle-mMCP-1. The pShuttle-mMCP-1 was digested with PI-SceI/I-CeuI (New England Biolabs, Hitchin, UK) and the purified product was ligated with Adeno-X genome DNA, containing nearly the full length of the adenovirus type 5 genome lacking the E1 and E3 regions, to generate pAd.mMCP-1. Subsequently, AdmMCP-1 was generated by transfecting 293 cells with pAd.mMCP-1, which was linearized with PacI, as described in the manual. Ad-sMCP-1 (which expresses sMCP-1), Ad-lacZ (which expresses beta-galactosidase (lacZ)) and Ad-tk (which expresses HSV-tk) were constructed as previously described and propagated in 293 cells (Figures 1b --d) . 9 The rAds were purified on a cesium gradient, and the titer of rAd was determined by the 50% tissue culture infectious dose (TCID 50 ) method. 10 Cell lines and culture
The mouse HCC cell lines (BNL 1NG A2, BNL 1ME A.7R. 1, MM45T.Li and Hepa 1-6) and the colon cancer cell line Colon 26 were used in these experiments. Cells were cultured in Dulbecco's modified Eagle medium (Gibco, Long Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Gibco).
ELISA for MCP-1
Aliquots of 1 Â 10 5 HCC lines (BNL 1NG A2, BNL 1ME A.7R. 1, MM45T.Li and Hepa 1-6) and the colon cancer cell line, Colon 26 clone 20, were seeded in 1.0 ml of culture media in a six-well tissue culture plate. After 24 h, the cells were infected with Ad-mMCP-1, Ad-sMCP-1 and Ad-lacZ at various multiplicities of infection (MOI). After 48 h, the cells were harvested and sonicated to obtain the membrane fractions, and the media was collected from each well. Tumor tissues were resected on day 1 after subcutaneous injection of 5 Â 10 6 MM45T.Li cells infected with indicated rAds (MOI 50) as described below. Tumor tissues were washed with phosphate-buffered saline (PBS) and sonicated to obtain the membrane fractions. The concentration of MCP-1 was determined by enzyme-linked immunosorbent assay (ELISA) as described previously. 11 Briefly, each well of a 96-well microtiter plate was coated with monoclonal anti-human MCP-1 antibody (ME61; 1 mg ml À1 ) overnight at 41 1C. After washing, the plates were blocked by incubation with PBS containing 1% bovine serum albumin for 1 h at 37 1C. Diluted sample media was added, and the plate was then incubated for 2 h at 37 1C. Following incubation, the plates were washed and incubated with rabbit anti-MCP-1 antibody (1 mg ml À1 ), followed by alkaline phosphataseconjugated goat anti-rabbit antibody (1/12 000, Tago, Burlingame, CA), each for 2 h at 37 1C. After the plate was washed, aliquots of 1 mg ml À1 p-nitrophenylphosphate (Sigma, St Louis, MO) in 1 M diethanolamine (Sigma; pH 9.8) supplemented with 0.5 mM MgCl 2 were added to the wells, and the plate was incubated for 40 min at room temperature. After the addition of 1 M NaOH, the optical density (405 nm wavelength---OD405) was assessed by using an ELISA plate reader (MTP-120; Corona Electric, Ibaragi, Japan).
In vitro chemotaxis assay
In vitro migration assays were performed with the QCM chemotaxis cell migration assay (5 mm, Chemicon International, Temecula, CA) according to the manufacturer's instructions. Briefly, 7.5 Â 10 4 splenocytes were resuspended in 100 ml of RPMI1640 containing 5% bovine serum albumin, and loaded into the upper well of a transwell chamber. The lower wells were filled with 150 ml of supernatant from MM45T.Li cells that were harvested 48 h after infection with rAds. The cells were incubated for 4 h at 37 1C in a humidified, 5% CO 2 atmosphere. The migrated cells were lysed and detected by the CyQuant GR dye (Molecular Probes, Eugene, OR), and fluorescence was read at an excitation wavelength of 490 nm and an emission wavelength of 520 nm in a fluorescence microplate reader (Thermo Scientific Fluoroskan Ascent FL, Thermo Fisher Scientific Oy, Vantaa, Finland). at 490 nm was measured by using an ELISA plate reader (MTP-120; Corona Electric).
In vitro proliferation assay
Animal studies
The following investigations were performed in accordance with the guidelines of our Institutional Animal Care and Use Committee. Six-weekold immunocompetent female BALB/c-jcl mice (CLEA Japan, Tokyo, Japan) were injected subcutaneously on both sides of the flank on day 0 with 3 Â 10 5 MM45T.Li cells infected with each rAd at an in vitro MOI of 5. For the next 5 days (days 1 --5), mice received 75 mg kg À1 of intraperitoneally administered GCV (Tanabe Pharmaceutical Drug, Tokyo, Japan). In some series of experiment, 1 mg of the recombinant human MCP-1 in 200 ml of PBS containing 1% bovine serum albumin were injected intraperitoneally, as previously described, 12 from days 0 to 2 (3 consecutive days) in the group of the tumor cells transduced with Ad-lacZ on HSV-tk/GCV suicide therapy. Tumor sizes were measured every 3 days, and tumor volumes were calculated according to the formula (longest diameter)/(shortest diameter) 2 /2.
Immunohistochemical analysis
Tumor tissues and spleens were resected on day 10. The tissue samples were embedded in OCT compound (Sakura Finetek, Toorrance, CA) and snap-frozen in liquid nitrogen. Cryostat sections of the frozen tissues were fixed with 4% paraformaldehyde in PBS, followed by washing once with distilled water for 5 min and three times with PBS for 5 min. To avoid nonspecific staining, avidin and biotin in the tissues were blocked by using a blocking kit (Vector Laboratories, Burlingame, CA).
The tissue sections were subsequently stained with rat anti-mouse CD4 Ab, rat anti-mouse CD8a Ab, rat anti-mouse CD11b Ab (BD Biosciences, San Diego, CA), or monoclonal mouse anti-human MCP-1 Ab (R&D systems, Minneapolis, MN) overnight at 4 1C. Isotype controls were also used. Then, the slides were incubated for 0.5 h at room temperature with biotinylated polyclonal rabbit anti-rat IgG (Dako Cytomation, Tokyo, Japan), or the antibodies in the M.O.M. immunodetection kit to detect mouse primary antibodies on mouse tissues (Vector Laboratories). The reactions were visualized by using a VectaStain ABC standard kit (Vector Laboratories), followed by counterstaining with hematoxylin. The positive cells were counted in 10 randomly chosen fields at 400-fold magnification by an examiner without any prior knowledge of the experimental procedures.
Quantitative real-time reverse-transcriptase PCR Total RNA was extracted from tumor tissues resected on day 10 using an RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After treating the RNA preparations with ribonuclease-free DNase I (Qiagen) to remove residual DNA, cDNA was synthesized as described previously. 13 Quantitative real-time PCR was performed on a StepOne real-time PCR system (Applied Biosystems, Foster City, CA) by using the comparative C T quantification method. TaqMan Gene Expression Assays (Applied Biosystems) containing specific primers (assay ID: tumor necrosis factor (TNF), Mm00443258_m1; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Mm99999915_g1), TaqMan MGB probe (FAM dyelabeled), and TaqMan Fast Universal PCR Master Mix were used with 10 ng cDNA to quantify the expression levels of TNF. Reactions were performed for 20 s at 95 1C followed by 40 cycles of 1 s at 95 1C and 20 s at 60 1C. The GAPDH was amplified as an internal control, and the GAPDH C T values were subtracted from C T values of the target genes (C T ). The DC T values of tumors after immune gene therapy with both the suicide gene (HSV-tk system) and rAds were compared respectively.
Flow cytometry MM45T .Li. cells transfected with rAds were resuspended in PBS containing 1% bovine serum albumin and 0.1% sodium azide and incubated for 30 min on ice with PE-conjugated rat anti-human MCP-1 (BD Pharmingen, San Diego, CA). The cells were washed, resuspended in PBS and analyzed in a FACScan with CellQuest software (FACSCalibur, BD Biosciences, San Jose, CA).
Depletion of macrophages/monocytes. Clodronate liposome was prepared and systemic depletion of monocytes/macrophages was performed as previously described. 14, 15 Mice were intraperitoneally injected with 200 ml of clodronate liposome five times: days À2, 0, 3, 6 and 10 after tumor injection. PBS-clodronate was given in the same manner as a negative control. Depletion of CD11c-negative monocytes in blood was confirmed by flow cytometry after injection of clodronate liposome.
Statistical analysis
Mean and s.d. or s.e. were calculated for the obtained data. The statistical significance of differences between groups was evaluated by the Mann --Whitney U-test. Po0.05 was considered statistically significant. (Figure 3a) . Next, tumor cells infected with rAds (MOI 10) ex vivo were transferred subcutaneously in syngeneic wild-type mice, and tumor development was monitored (Figure 3b ). Tumor cells infected with Ad-mMCP-1 and Ad-sMCP-1 showed similar growth rates to tumor cells infected with Ad-lacZ. These results indicate that infection with the rAds used in this study did not affect the proliferation of tumor cells in vitro and in vivo, and that the delivery of mMCP-1 did not display antitumor activity when used alone. In addition, the levels of MCP-1 expression were confirmed immunohistochemically in the subcutaneous tumor tissues (Figure 3c ). MCP-1-positive tumor cells were detected in tumor tissues infected with Ad-mMCP-1; however, the cells were negative for MCP-1 staining in tissues infected with Ad-sMCP-1 and Ad-lacZ. Moreover, larger amounts of MCP-1 were detected in the tumor tissues of the mice treated with Ad-mMCP-1 than in those with Ad-sMCP-1 (Figure 3d ). The data indicated that large amounts of MCP-1 protein were expressed and accumulated on the tumor cell surface when the tumor cells were infected with Ad-mMCP-1 in vivo.
RESULTS
In vitro
and in vivo MCP-1 production by cells infected with recombinant adenoviruses When various tumor cells were infected with either Ad-mMCP-1 or Ad-sMCP-1
Potentiation of HSV-tk/GCV suicide therapy by co-infection with Ad-mMCP-1
We previously demonstrated that the gene delivery of Ad-sMCP-1 enhanced the antitumor effects of the HSV-tk/GCV system. 4--6,16,17 Hence, we compared the effects of Ad-mMCP-1 and Ad-sMCP-1 infection on HSV-tk/GCV suicide therapy. When MM45T.Li cells were co-infected with Ad-tk and Ad-lacZ, and received GCV, tumor growth was delayed marginally but not significantly (Figure 4a ).
Co-infection with Ad-tk and Ad-sMCP-1 retarded tumor growth significantly after GCV treatment. Moreover, tumor growth was almost abrogated by the combination of co-infection with Ad-tk and Ad-mMCP-1, and GCV treatment. To address whether the antitumor effects could be induced not only by the gene delivery using Ad vector, but also by the administration of recombinant protein, we gave intraperitoneally recombinant MCP-1 to the animals, which were injected with tumor cells, treated with Ad-lacZ and Ad-tk. The systemic administration of recombinant MCP-1 rather enhanced tumor growth ( Figure 4b ). As we previously demonstrated that MCP-1 can promote tumor growth in a context-dependent manner by recruiting macrophages, which can secrete an angiogenic factor, the vascular endothelial growth factor, 16, 18 systemic MCP-1 injection may promote tumor growth by its pro-angiogenic activities.
Recruitment and activation of macrophages and T lymphocytes in tumor tissues
The GCV treatment following co-infection with Ad-lacZ and Ad-tk failed to increase the intratumoral numbers of Mac-1-positive macrophages, CD4-positive lymphocytes and CD8-positve lymphocytes, compared with GCV treatment following Ad-lacZ infection ( Figures 5A and B) . GCV administration following coinfection with Ad-sMCP-1 and Ad-tk increased the intratumoral Mac-1-positive macrophage, CD4-positive lymphocyte and CD8-positve lymphocyte numbers ( Figure 5A and B) . The increases were further enhanced by GCV treatment following co-infection with Ad-mMCP-1 and Ad-tk ( Figures 5A and B) . Moreover, intratumoral mRNA expression of TNF, a known macrophage and T lymphocyte secretagogue, was markedly enhanced in tumors co-infected with Ad-mMCP-1, compared with those with Ad-sMCP-1 plus Ad-tk. To evaluate the functional contribution of intratumoral immune cells, we depleted CD11c-negative monocytes/macrophages by intraperitoneal administration of clodronate liposome in the current mouse model. The monocyte/ macrophage-depleted mice developed larger tumor than those treated with PBS liposome (Figure 5D ), indicating that monocytes/ macrophages were critically involved in the suppression of tumor growth by Ad-mMCP-1. Collectively, these data demonstrate that the delivery of mMCP-1 promoted the recruitment and activation of macrophages and T lymphocytes in tumor tissues, presumably leading to the beneficial antitumor responses in this model.
DISCUSSION
We have proposed a strategy for improving the efficacy of suicide gene-based gene therapy by the combined heterochronic administration of HSV-tk and MCP-1 genes. 4 --6,16 --18 In the current study, we generated recombinant adenovirus Ad-mMCP-1 expressing a fusion protein containing the human MCP-1 cDNA fused with the membrane-spanning domain of fractalkine/CX3CL1, to drive more efficient and sessile expression of MCP-1. Ad-mMCP-1 infection did not affect the proliferation of MM45T.Li tumor cells in vitro or in vivo, by itself. Of interest is that Ad-mMCP-1 infection pontentiated HSV-tk/GCV suicide therapy more efficiently than Ad-sMCP-1. Moreover, Ad-mMCP-1-mediated antitumor effects were associated with the recruitment and activation of macrophages and T lymphocytes in tumor tissues. Collectively, the delivery of membrane-bound MCP-1 gene can augment antitumor effects caused by the HSV-tk/GCV system in an immunecompetent mouse model of liver tumor and therefore, can be a novel strategy of immune-based gene therapy to prevent tumor proliferation and recurrence in patients with HCC.
Chimeric membrane-bound cytokine gene expression vectors were generated to drive the efficient expression on tumor cell surface and to reduce the severe side effects caused by systemic administration of high doses of cytokines. With this maneuver, cytokines can be anchored on the cell plasma membrane. As a consequence, a locally high concentration of cytokines can be achieved with ease and their in vivo half-life can be prolonged in the tumor site. The availability of cytokines on tumor cell surface can eventually bring immune cells to the tumor site for better antigen uptake and stimulation, thereby inducing antitumor effects at a higher efficiency. On the basis of these assumptions, this type of modified cytokine gene therapy has been reported on interleukin-2, 13, 19, 20 interleukin-12, 21 fractalkine (CX3CL1) 22 and TNF. 23 Indeed, accumulating evidence revealed that the membrane-bound form of cytokine genes can exhibit more antitumor effects than the corresponding soluble ones. Likewise, the current study confirms that the membrane-bound form of MCP-1 can attract more immune cells, including monocytes/macrophages and T lymphocytes, to the tumor sites and can induce the expression of TNF. In addition, TNF can activate endothelial cells to express several adhesion molecules, such as the intercellular adhesion molecules and vascular cell adhesion molecules. 24 --27 Circulating immune cells can utilize these adhesion molecules to effectively transmigrate into the tissues in addition to the direct chemotactic activities exerted by MCP-1.
The effects of MCP-1 on tumor growth was controversial, either destructive 28 --30 or protective 31, 32 in a context-dependent manner. Likewise, murine colon carcinoma cell expressing MCP-1 failed to metastasize when injected into mice, 28 whereas other carcinoma cells showed enhanced metastasis. 31 These discrepancies may be explained by the observations reported by Nesbit et al.
33 They demonstrated that low-level MCP-1 secretion with modest monocyte infiltration resulted in tumor formation, whereas high secretion was associated with massive monocyte/macrophage infiltration into the tumor mass, leading to its destruction within a few days. Thus, systemic MCP-1 administration may not be able to induce massive monocyte/macrophage infiltration into tumor mass and may promote tumor mass as we observed in the present study. Moreover, we previously revealed that suicide therapy can induce tumor cell apoptosis and that apoptotic tumor cells can secrete MCP-1 more efficiently, thereby recruiting a massive number of macrophages and retarding tumor growth. 4 Consistently, we further demonstrated that the delivery of an optimal amount of rAd expressing MCP-1 enhanced the antitumor effects of the HSV-tk/GCV system in a model of HCC. 16, 18 Infection with Ad-mMCP-1 can sustain MCP-1 expression in tumor tissues more efficiently than that with Ad-sMCP-1 as evidenced by an immunohistochemical analysis on the infected tumor tissues. The sustained MCP-1 expression can potentiate suicide gene therapy more efficiently.
The present data suggest that the use of Ad-mMCP-1 can be promising, but several problems remain to be solved before the clinical application. First, subcutaneous tumor models of an HCC cell line may not be relevant to HCCs in patients. However, in cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous radiofrequency ablation therapy 34 and MM45T.Li cells infected with rAds Ad-membrane-bound monocyte chemoattractant protein-1 (mMCP-1) þ Ad-tk, Ad-soluble MCP-1 (sMCP-1) þ Ad-tk, Ad-lacZ þ Ad-tk, and Ad-lacZ at multiplicities of infection (MOI) of 10 on day 0. Subsequently, 75 mg kg À1 of ganciclovir (GCV) was administered for 5 consecutive days (days 2 --6). Each value is the mean s.e. of triplicate experiments. *Po0.05 when compared with Ad-sMCP-1 þ Ad-tk, and **Po0.01 when compared with Ad-lacZ þ Ad-tk by the Mann --Whitney's U-test. (b) BALB/c mice were injected with MM45T.Li cells and treated as described in the legend to (a). In Ad-lacZ þ Ad-tk þ recombinant human MCP-1 (rMCP-1) group, the mice were injected with 1 mg of rMCP-1 intraperitoneally from days 0 to 2 (3 consecutive days). The mice were injected with phosphate-buffered saline (PBS) as controls. Tumor sizes were measured every 3 days. Each value is the mean s.e. **Po0.01 when compared with Ad-lacZ þ Ad-tk þ rMCP-1 by the Mann --Whitney's U-test.
transcatheter arterial chemotherapy, 35 administration of the current rAd vectors could be easily applied, immediately once the standard nonsurgical procedures to ensure tumor cell killing. Moreover, rAd can elicit its immunogenicity or cytotoxicity when administered in HCC patients, particularly by the use of intraarterial procedures. Actually, the infection of high doses of rAds causes severe unexpected side effects. 36 However, the delivery of membrane-bound form of the MCP-1 gene can cause Figure 4a . In the Ad-mMCP-1 þ Ad-tk þ clodronate liposome (CL) group, mice were injected with 200 ml of CL to deplete monocytes/macrophages as described in Materials and methods. The mice were injected with phosphatebuffered saline (PBS) liposome as controls. Tumor sizes were measured every 3 days. Each value is the mean s.e. *Po0.05 when compared with Ad-mMCP-1 þ Ad-tk þ PBS by the Mann --Whitney's U-test. a high and effective concentration at the tumor sites even when it is administered at a relatively lower titer, and therefore, can evade severe adverse effects caused frequently by the administration of a high titer of adenovirus vectors.
